iShares Genomics Immunology and Healthcare ETF (IDNA) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.35: the stock has moved about 35% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnsweriShares Genomics Immunology and Healthcare ETF (IDNA) trades at $42.72. The iShares Genomics Immunology and Healthcare ETF (IDNA) aims to track the investment results of an index focused on companies benefiting from advancements in genomics, immunology, and bioengineering. Sector: Financials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for IDNA: IDNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
iShares Genomics Immunology and Healthcare ETF (IDNA) Financial Services Profile
iShares Genomics Immunology and Healthcare ETF (IDNA) offers investors targeted exposure to companies poised to benefit from long-term growth trends in genomics, immunology, and bioengineering. With a focus on both developed and emerging markets, IDNA provides a diversified investment vehicle for capitalizing on innovation within the healthcare sector, while exhibiting a beta of 1.35.
What Is the Investment Thesis for IDNA?
The iShares Genomics Immunology and Healthcare ETF (IDNA) presents an investment opportunity centered on the long-term growth potential of genomics, immunology, and bioengineering. The ETF's focus on companies in both developed and emerging markets allows investors to capitalize on global innovation trends within the healthcare sector. With a beta of 1.35, IDNA exhibits moderate volatility relative to the broader market. Key value drivers include the increasing demand for personalized medicine, the development of novel immunotherapies for cancer and other diseases, and the application of bioengineering technologies to address unmet medical needs. Upcoming catalysts include regulatory approvals for new therapies, advancements in genomic sequencing technologies, and increased investment in healthcare infrastructure in emerging markets. Potential risks include regulatory hurdles, clinical trial failures, and competitive pressures from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
IDNA Key Highlights
Market capitalization of $0.16 billion, indicating a relatively small-cap ETF.
- Beta of 1.35, suggesting higher volatility compared to the broader market.
- Exposure to both developed and emerging market companies in the genomics, immunology, and healthcare sectors.
- Focus on companies that could benefit from long-term growth and innovation in these fields.
- Managed by BlackRock, a leading global asset management firm.
Who Are IDNA's Competitors?
IDNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| DALI First Trust Dorsey Wright DALI Equity ETF | $28.47 | +0.71% | $107M | — |
| DEW WisdomTree Global High Dividend Fund | $68.67 | -0.09% | $134M | — |
| ECOW Pacer Emerging Markets Cash Cows 100 ETF | $26.73 | +2.32% | $148M | — |
| EMXF iShares ESG Advanced MSCI EM ETF | $58.45 | +1.40% | $167M | — |
| EWO iShares MSCI Austria ETF | $41.79 | +0.07% | $175M | — |
| BLK BlackRock, Inc. | $1066.45 | +0.64% | $165B | 51 5-pillar |
| BX Blackstone Inc. | $111.64 | -0.09% | $136B | 68 5-pillar |
| APOS Apollo Global Management, Inc. | $25.59 | 0.00% | $74.8B | 56 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IDNA's Key Strengths?
Exposure to high-growth sectors: genomics, immunology, and bioengineering.
- Diversified portfolio of companies in both developed and emerging markets.
- Managed by BlackRock, a leading global asset management firm.
- Focus on long-term growth trends in innovative healthcare fields.
What Are IDNA's Weaknesses?
Relatively small market capitalization, which may limit liquidity.
- Higher beta compared to the broader market, indicating greater volatility.
- Concentration in specific sectors, which may increase risk.
- Dependence on the performance of companies in the genomics, immunology, and healthcare sectors.
What Are the Key Risks for IDNA?
Clinical trial failures and setbacks in drug development.
- Regulatory hurdles and changes in government policies.
- Economic downturns impacting healthcare spending.
- Competitive pressures from established pharmaceutical companies.
- Market volatility and fluctuations in stock prices.
What Are IDNA's Competitive Advantages?
- Brand recognition and reputation of BlackRock, a leading global asset management firm.
- Diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
- Exposure to both developed and emerging markets.
- Focus on long-term growth trends in innovative healthcare fields.
What Does IDNA Do?
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to provide investors with exposure to companies that are expected to benefit from the ongoing advancements and long-term growth in the fields of genomics, immunology, and bioengineering. Managed by BlackRock, a leading global asset management firm, IDNA seeks to replicate the investment results of an underlying index composed of equities from both developed and emerging markets. The ETF's holdings span a range of companies involved in various aspects of these innovative sectors, including biotechnology firms, pharmaceutical companies, and providers of healthcare services and equipment. IDNA's investment strategy focuses on identifying companies that are at the forefront of genomic research, developing novel immunotherapies, and pioneering bioengineering technologies. By investing in a diversified portfolio of companies within these fields, the ETF aims to capture the potential upside from breakthroughs and advancements that could transform healthcare and improve patient outcomes. The ETF's global reach allows investors to tap into growth opportunities in both established and emerging markets, providing a broader perspective on the evolving landscape of genomics, immunology, and healthcare. As of 2026, IDNA has a market capitalization of $0.16 billion.
What Products and Services Does IDNA Offer?
- Tracks the investment results of an index composed of developed and emerging market companies.
- Focuses on companies that could benefit from long-term growth and innovation in genomics.
- Targets companies involved in immunology research and development.
- Includes companies engaged in bioengineering technologies.
- Provides investors with exposure to the healthcare sector.
- Offers a diversified portfolio of companies within these innovative fields.
- Aims to capture the potential upside from breakthroughs and advancements in healthcare.
How Does IDNA Make Money?
- The ETF generates revenue through management fees charged to investors.
- The fund invests in a diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
- The ETF seeks to replicate the investment results of an underlying index.
- The ETF's performance is driven by the growth and innovation of the companies it holds.
What Industry Does IDNA Operate In?
The asset management industry is characterized by increasing competition, evolving regulatory landscapes, and growing demand for specialized investment products. ETFs like IDNA cater to investors seeking targeted exposure to specific sectors or themes, such as genomics and immunology. The global healthcare market is experiencing rapid growth, driven by factors such as an aging population, rising healthcare expenditures, and technological advancements. IDNA's focus on genomics, immunology, and bioengineering aligns with the broader trend towards personalized medicine and innovative therapies. Competitors in the ETF space include firms offering similar thematic or sector-specific investment products.
Who Are IDNA's Key Customers?
- Individual investors seeking exposure to the genomics, immunology, and healthcare sectors.
- Institutional investors looking for thematic investment opportunities.
- Financial advisors seeking to diversify client portfolios.
- Investors interested in long-term growth potential in the healthcare industry.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 42 snapshots
| 2026-08-23 | 47 |
| 2026-08-31 | 47 |
| 2026-09-08 | 47 |
| 2026-09-16 | 47 |
| 2026-09-24 | 47 |
| 2026-10-04 | 47 |
| 2026-10-05 | 47 |
What changed?
The score has stayed at 47.
Over the same 30 days the stock moved +7.4%.
IDNA Financials
Bull Case vs Bear Case
Bull Case
- Exposure to high-growth sectors: genomics, immunology, and bioengineering.
- Diversified portfolio of companies in both developed and emerging markets.
- Managed by BlackRock, a leading global asset management firm.
- Focus on long-term growth trends in innovative healthcare fields.
Bear Case
- Relatively small market capitalization, which may limit liquidity.
- Higher beta compared to the broader market, indicating greater volatility.
- Concentration in specific sectors, which may increase risk.
- Dependence on the performance of companies in the genomics, immunology, and healthcare sectors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IDNA Latest News
-
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
benzinga · Sep 1, 2026
-
IDNA: 3 Catalysts To Watch Closely
seekingalpha.com · Aug 21, 2026
-
Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
benzinga · Aug 19, 2026
IDNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IDNA.
Price Targets
Wall Street price target analysis for IDNA.
IDNA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IDNA; grades run from A+ (80-100) to F (below 30).
Common Questions About IDNA (Financials)
What regulatory challenges does iShares Genomics Immunology and Healthcare ETF face?
As an ETF, iShares Genomics Immunology and Healthcare ETF (IDNA) is subject to regulations governing investment companies and ETFs. These regulations include requirements for diversification, liquidity, and transparency. The ETF must also comply with securities laws and regulations related to trading and disclosure.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The analysis is based on publicly available information and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.